Pioneering Medical Innovations
151 subjects enrolled in various stages of loading and randomization in SOL-1 pivotal study of AXPAXLI in wet AMD as
Clinical investigators achieve significant milestone by enrolling 150 patients with hypervascular tumors in pivotal randomized study. BEDFORD, Mass., – May
46.2% of patients demonstrated a 1- or 2-step improvement in the Diabetic Retinopathy Severity Scale (DRSS) at 40 weeks in
Phase 2 data highlight consistent and sustained reductions in Intraocular Pressure (IOP), statistically significant (p<0.0001) through six months, with clinically
Phase 3 SOL-1 study will evaluate the efficacy and safety of AXPAXLI in wet AMD BEDFORD, Mass., Feb. 13, 2024 (GLOBE NEWSWIRE)
Axtria Inc., a global leader in cloud software and data analytics for the life sciences industry, announced it is again
SPA amendment expands eligibility criteria for SOL clinical trial Broadening of eligibility criteria anticipated to accelerate overall trial enrollment BEDFORD,
Data calls attention to stroke survivor independence, readmissions, quality of life and adherence to discharge plans December 06, 2023 08:00
First patients treated with investigational Neurovascular Stent System by Dr. Nobuyuki Sakai at Kobe City Medical Center General Hospital, Japan
Late-Breaking Data Presented at the Society of NeuroInterventional Surgery Annual Meeting Demonstrate High Rates of Successful Reperfusion and Rapid Procedure